- Orphan drug designation from the European Commission underscores Solid's commitment to advance SGT-003 through a global development effort for individuals living with Duchenne muscular dystrophy - 

CHARLESTOWN, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the European Commission (EC), acting upon the positive opinion from the European Medicines Agency Committee for Orphan Medicinal Products, has granted Orphan drug designation to SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne).